Loading stock data…
Arbutus Biopharma Corporation (ABUS)
$4.67+0.10 (+2.07%)
Market OpenUpdated 2:03 PM EDT
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arbutus Biopharma Corporation in the Healthcare sector is trading at $4.67 with a market capitalization of $859M. Wall Street consensus targets $5.07 (2 analysts), implying a +8.5% move over the next 12 months. The stock is currently 8% below its 52-week high of $5.10, remaining 5.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +8.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $179.13M↑ | $1.05M↑ | $529,000↓ | $10.74M↑ | $1.76M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $169.12M↑ | -$7.64M↑ | -$8.29M↓ | $1.91M↑ | -$13.03M |
| Net Income | $169.69M↑ | -$3.76M↑ | -$7.74M↓ | $2.52M↑ | -$24.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$859.29M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
5.24
Beta
Defensive asset. Lower volatility than the S&P 500.
0.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
61.77%
Volume
Today's trading volume
910,711
Recent News
Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results
Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the 10 Most Profitable Small Cap Stocks to Buy. On May 13, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported Q1 2026 revenue of $179.1 million with estimated license revenue tied to its litigation settlement with Moderna. The company said revenue jumped from $1.8 million a year earlier because of […]
The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals
Moderna jumps despite a Q1 loss as strong international vaccine sales drive revenue surge and boost investor sentiment.
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway.
Moderna defied expectations of a Covid-revenue slowdown on Friday as a surge in international vaccine sales underpinned its first-quarter results. Revenue more than tripled in Moderna’s latest quarter to $389 million from $108 million last year, handily beating analysts’ calls for $236.4 million. Moderna logged a $1.34 billion net loss, or $3.40 a share.
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales
MRNA narrows Q1 loss and beats revenue estimates as international vaccine sales surge, lifting shares despite hefty litigation charges.
Moderna Q1 2026 earnings beat on international COVID vaccine sales
The company posted $389 million in first-quarter revenue, well above analyst expectations, with 80% coming from international markets